What does iShares MSCI Israel ETF do?

iShares MSCI Israel ETF (NYSE Arca: EIS) is an exchange-traded fund (ETF), not an individual company. An ETF is a basket of many stocks packaged into a single instrument you buy and sell like a stock. It's issued by iShares (BlackRock). What it holds: it tracks the MSCI Israel index, which groups the large- and mid-cap companies of Israel (~129 companies, ~85% of the country's investable market). Its biggest positions (top 10, ~Jun 2026): Teva Pharmaceutical (pharma) ~8.8% Bank Leumi (bank) ~8.0% Bank Hapoalim (bank) ~7.0% Tower Semiconductor (chips) ~6.9% Elbit Systems (defense) ~5.4% Nova (chip equipment) ~3.4%, Phoenix Financial (insurance) ~3.3%, Enlight Renewable Energy ~3.2%, Israel Discount Bank ~3.0%, Mizrahi Tefahot Bank ~2.6% The dominant themes: banking (Leumi, Hapoalim, Discount, Mizrahi add up to ~20% of the fund), health (Teva), semiconductors (Tower, Nova) and defense (Elbit) — the heart of the 'startup nation'. Costs and income: it charges an expense ratio of 0.59% a year and pays a modest dividend of ~1.1% a year (semi-annual distribution), which comes from the dividends of the Israeli companies it holds. Assets (AUM): ~$1.0 billion. Why it enters the portfolio: even though it's a basket and not a single company, it also pays dividends — it fits the 'own things that pay you' thesis — and gives diversified exposure to a developed, resilient and very tech-heavy economy for a reasonable fee. It also reinforces today's pick: Bank Hapoalim lives inside this fund.

Why did Vectorial Data pick EIS?

EIS at $125.61 is the simplest, most diversified way to get exposure to Israel — the 'startup nation' — in a single buy, without depending on one company. Specific reasons: (1) Exposure to the whole Israeli economy at once: solid, cheap banks (Leumi, Hapoalim, Discount, Mizrahi ~20% of the fund), the world's largest generics pharma (Teva), chipmakers (Tower, Nova) and defense champion Elbit — one buy gives you finance, health, semiconductors and defense. (2) Proven resilience: despite years of geopolitical tension and war in the region, the Israeli market has been surprisingly resilient — it's a developed economy, not a fragile emerging market. (3) Defense theme with a tailwind: Elbit Systems and the Israeli defense ecosystem benefit from rising global military spending. (4) Reasonable fee (0.59%) and it pays you dividends (~1.1%): unlike betting on a single company, this basket distributes the dividend from its ~129 companies, twice a year. (5) Real diversification: instead of picking one bank or one Israeli tech name, you hold the biggest ones in a single instrument. (6) Synergy with the portfolio: today we also bought Bank Hapoalim separately — EIS gives you that bank PLUS the rest of Israel. It's country exposure, diversified and with some income.

What are the risks of investing in EIS?

Risks: (1) Geopolitical risk — #1: Israel sits in one of the world's most conflict-prone regions; a war or escalation (with Iran, Gaza, Lebanon) can hit the whole market at once and without warning. It's the risk that defines this ETF. (2) Currency risk (the shekel): the ETF trades in dollars but its stocks are in Israeli shekels; if the shekel weakens against the dollar, your return drops even if the stocks rise locally. (3) Concentration: the 10 largest names are more than half the fund, and a single sector (banking) weighs ~20% — it's not 'infinitely diversified Israel'. (4) Dependence on Teva: the biggest position is Teva (~8.8%), a pharma with a lot of historical debt and exposed to the generics price war; if it stumbles, the fund feels it. (5) Modest dividend (~1.1%): it pays less than our other ETFs (FLKR ~2%, EZA ~6%) — the thesis here is exposure + resilience, not high income. (6) No 'active management': an ETF tracks the index blindly — if the index is heavy in banking or in Teva, you carry that imbalance.

Is EIS an ETF or a stock?

iShares MSCI Israel ETF is an ETF (exchange-traded fund): one purchase gives you a small piece of many companies at once, instead of a single company.

How can I buy EIS with little money?

You can buy fractional shares of EIS starting from a few dollars with any broker that offers fractional shares. The Vectorial Data method: invest the same amount in every pick, every time.

When was this EIS analysis last updated?

The EIS analysis was last updated on Invalid Date.

Stocks/EIS

EIS — iShares MSCI Israel ETF

ETFMiddle EastIsraelBlockchain certified

$125.61

Target: $ (%)

P/E Ratio

—

P/E Forward

—

Dividend

1.14%

Market Cap

$1.03B

EPS

—

Consensus

ETF — canasta indexada (sin rating individual)

What they do

iShares MSCI Israel ETF (NYSE Arca: EIS) is an exchange-traded fund (ETF), not an individual company. An ETF is a basket of many stocks packaged into a single instrument you buy and sell like a stock. It's issued by iShares (BlackRock).

What it holds: it tracks the MSCI Israel index, which groups the large- and mid-cap companies of Israel (~129 companies, ~85% of the country's investable market).

Its biggest positions (top 10, ~Jun 2026):

Teva Pharmaceutical (pharma) ~8.8%
Bank Leumi (bank) ~8.0%
Bank Hapoalim (bank) ~7.0%
Tower Semiconductor (chips) ~6.9%
Elbit Systems (defense) ~5.4%
Nova (chip equipment) ~3.4%, Phoenix Financial (insurance) ~3.3%, Enlight Renewable Energy ~3.2%, Israel Discount Bank ~3.0%, Mizrahi Tefahot Bank ~2.6%

The dominant themes: banking (Leumi, Hapoalim, Discount, Mizrahi add up to ~20% of the fund), health (Teva), semiconductors (Tower, Nova) and defense (Elbit) — the heart of the 'startup nation'.

Costs and income: it charges an expense ratio of 0.59% a year and pays a modest dividend of ~1.1% a year (semi-annual distribution), which comes from the dividends of the Israeli companies it holds. Assets (AUM): ~$1.0 billion.

Why it enters the portfolio: even though it's a basket and not a single company, it also pays dividends — it fits the 'own things that pay you' thesis — and gives diversified exposure to a developed, resilient and very tech-heavy economy for a reasonable fee. It also reinforces today's pick: Bank Hapoalim lives inside this fund.

Why we like it

EIS at $125.61 is the simplest, most diversified way to get exposure to Israel — the 'startup nation' — in a single buy, without depending on one company. Specific reasons:

Exposure to the whole Israeli economy at once: solid, cheap banks (Leumi, Hapoalim, Discount, Mizrahi ~20% of the fund), the world's largest generics pharma (Teva), chipmakers (Tower, Nova) and defense champion Elbit — one buy gives you finance, health, semiconductors and defense.
Proven resilience: despite years of geopolitical tension and war in the region, the Israeli market has been surprisingly resilient — it's a developed economy, not a fragile emerging market.
Defense theme with a tailwind: Elbit Systems and the Israeli defense ecosystem benefit from rising global military spending.
Reasonable fee (0.59%) and it pays you dividends (~1.1%): unlike betting on a single company, this basket distributes the dividend from its ~129 companies, twice a year.
Real diversification: instead of picking one bank or one Israeli tech name, you hold the biggest ones in a single instrument.
Synergy with the portfolio: today we also bought Bank Hapoalim separately — EIS gives you that bank PLUS the rest of Israel. It's country exposure, diversified and with some income.

Key Risk

Risks:

Geopolitical risk — #1: Israel sits in one of the world's most conflict-prone regions; a war or escalation (with Iran, Gaza, Lebanon) can hit the whole market at once and without warning. It's the risk that defines this ETF.
Currency risk (the shekel): the ETF trades in dollars but its stocks are in Israeli shekels; if the shekel weakens against the dollar, your return drops even if the stocks rise locally.
Concentration: the 10 largest names are more than half the fund, and a single sector (banking) weighs ~20% — it's not 'infinitely diversified Israel'.
Dependence on Teva: the biggest position is Teva (~8.8%), a pharma with a lot of historical debt and exposed to the generics price war; if it stumbles, the fund feels it.
Modest dividend (~1.1%): it pays less than our other ETFs (FLKR ~2%, EZA ~6%) — the thesis here is exposure + resilience, not high income.
No 'active management': an ETF tracks the index blindly — if the index is heavy in banking or in Teva, you carry that imbalance.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked EIS on 2026-06-16 at $125.61.

Last updated: Invalid Date

Dividends received by the Vectorial portfolio

EIS has not paid a dividend to the portfolio yet.

Full Research

iShares MSCI Israel ETF (EIS) — Research Completo

Precio: $125.61 | Tipo: ETF | Expense ratio: 0.59% | Div Yield: ~1.1% | AUM: ~$1.0B USD

⚠️ Esto es un ETF, no una empresa

EIS es una canasta de ~129 empresas grandes y medianas de Israel empaquetada en un solo instrumento. No tiene CEO ni un solo negocio: es exposición diversificada a un país. Emisor: iShares (BlackRock). Índice: MSCI Israel.

Qué contiene (top 10, ~jun 2026)

#	Empresa	Sector	Peso
1	Teva Pharmaceutical	Salud (genéricos)	8.8%
2	Bank Leumi	Banco	8.0%
3	Bank Hapoalim	Banco	7.0%
4	Tower Semiconductor	Chips	6.9%
5	Elbit Systems	Defensa	5.4%
6	Nova	Equipo de chips	3.4%
7	Phoenix Financial	Seguros	3.3%
8	Enlight Renewable Energy	Renovables	3.2%
9	Israel Discount Bank	Banco	3.0%
10	Mizrahi Tefahot Bank	Banco	2.6%

Top 10 ≈ 51% del fondo. Solo la banca (Leumi + Hapoalim + Discount + Mizrahi) ≈ 20%.

Temas dominantes

Tema	Nombres
Banca (~20%)	Leumi, Hapoalim, Discount, Mizrahi
Salud	Teva (el mayor de genéricos del mundo)
Semiconductores	Tower, Nova
Defensa	Elbit Systems

Datos clave

Métrica	Valor
Expense ratio	0.59% /año
Dividend yield (TTM)	~1.1% (distribución semestral)
AUM	~$1.0 mil millones
Nº de holdings	~129

Anchor Fact

Comprar EIS es comprar el corazón de la 'nación startup' en una sola operación: sus cuatro grandes bancos, su gigante farmacéutico Teva, sus fabricantes de chips (Tower, Nova) y su campeón de defensa Elbit. Y pese a vivir en una de las regiones más conflictivas del planeta, el mercado israelí ha sido históricamente resiliente —es una economía desarrollada, no un emergente frágil—. Curiosidad: Bank Hapoalim, nuestro otro pick de hoy, es la tercera mayor posición del fondo.

Top Risks

Geopolítico — guerra/escalada regional puede golpear todo de golpe
Moneda (shekel) — cotiza en USD, holdings en shekels
Concentración — top 10 ≈ 51%, banca ≈ 20%
Dependencia de Teva — mayor posición, deuda histórica + genéricos
Dividendo modesto (~1.1%) — menos que FLKR/EZA

¿Por qué entra al portafolio?

Aunque es una canasta y no una sola empresa, también paga dividendos (~1.1%), encaja con la tesis de 'tener cosas que te pagan', y da exposición barata (0.59%) y diversificada a una economía desarrollada, tecnológica y resiliente. Además refuerza el pick de hoy: Bank Hapoalim vive dentro del fondo.

Tesis en una línea

La forma más simple de tenerle exposición a Israel —su banca, Teva, sus chips y su defensa— en una sola compra, por una comisión de 0.59% y con algo de dividendo, apostando a la resiliencia de una economía desarrollada en una región difícil.

Research fecha: 16 Jun 2026 | Próxima revisión: Dic 2026

Esto no es asesoría financiera.

More picks in ETF

See all ETF picks →

More picks from Israel

See all picks from Israel →

Researched: 6/16/2026Updated: 6/16/2026Next review: 12/16/2026

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.